Pyxis Oncology rises on nod for early stage trials of solid tumor drugs

Pyxis Oncology

01/12/2022 13:05

** Shares of drug developer Pyxis Oncology Inc  PYXS.O  rise
16.5% to $1.69 premarket
    ** U.S. FDA approves initiation of early stage trial of
company's two experimental drugs to treat patients with select
solid tumors  urn:newsml:reuters.com:*:nGNX8y22lt
    ** Trial will assess safety and anti-tumor activity
    ** Stock down ~87% YTD, through Wednesday close
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))